Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects.
Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects.
复制标题
中医药治疗肺纤维化的进展与未来展望
DOI：
10.1016/j.jep.2016.12.042
复制
发表时间：
2017-02-23
影响因子：
5.4
通讯作者：
Kan LD
中科院分区：
文献类型：
--
作者：
Li LC;Kan LD
肺纤维化（PF）是一种慢性、使人衰弱且常常致命的肺部疾病。尽管PF的分子机制随着众多研究人员的努力逐渐清晰，但很少有有效的药物被开发出来以逆转人类PF或甚至阻止慢性进展为呼吸衰竭。传统中医药是已有5000多年历史的医疗实践的主要组成部分，尤其是在中国，在治疗人类疾病方面，它的作用范围往往比以前尝试的选择更广泛。近年来的研究表明，中药及其有效成分具有抗纤维化的作用，这可能是抗纤维化药物的一个有吸引力的来源。本文综述了中药及其有效成分的临床前和临床证据，为探索植物药治疗肺纤维化的新策略提供了全面的信息和可靠的依据。文献信息来源于民族植物学和民族医药科学数据库（截至2016年8月），主要来源于Pubmed、Web of Science和CNKI数据库，旨在识别中药活性药物抗纤维化作用及其机制的实验研究。这类工作的搜索关键词包括：“肺纤维化”或“肺纤维化”，以及“传统中药”、“提取物”或“草药”。大量研究表明，单味中药和中药方剂的活性成分，尤其是黄酮类、苷类和生物碱类成分，对PF具有潜在的治疗作用，其机制可能涉及炎症调节、氧化应激、促纤维化信号通路等方面，并对中药治疗PF的炮制方法进行了展望。这些研究工作已经显示了中医药在治疗PF中的疗效，但仍需进行更多的后续研究，以阐明尚未证实的化学成分和调控机制，进行规范的临床试验，并评估可能的副作用。本综述提供的见解将需要进一步探索植物药在PF治疗的发展。
Pulmonary fibrosis (PF) is a chronic, debilitating and often lethal lung disorder. Despite the molecular mechanisms of PF are gradually clear with numerous researchers’ efforts, few effective drugs have been developed to reverse human PF or even halt the chronic progression to respiratory failure. Traditional Chinese medicine (TCM), the main component of the medical practice used for more than 5000 years especially in China, often exerts wider action spectrum than previously attempted options in treating human diseases. Recent data have shown the anti-fibrotic benefits of the active ingredients from TCM in this field, which may represent an attractive source of the drug discovery against PF. This review summarizes the pre-clinical and clinical evidence on the benefits of TCM and their active ingredients, and provides a comprehensive information and reliable basis for the exploration of new treatment strategies of botanical drugs in the therapy of PF. The literature information was obtained from the scientific databases on ethnobotany and ethno medicines (up to Aug 2016), mainly from the Pubmed, Web of Science and CNKI databases, and was to identify the experimental studies on the anti-fibrotic role of the active agents from TCM and the involved mechanisms. The search keywords for such work included: “lung fibrosis” or “pulmonary fibrosis”, and “traditional Chinese medicine”, “extract” or “herb”. A number of studies have shown that the active agents of single herbs and TCM formulas, particularly the flavonoids, glycosides and alkaloids, exhibit potential benefits against PF, the mechanisms of which appear to involve the regulation of inflammation, oxidant stress, and pro-fibrotic signaling pathways, etc. Besides, the processing methods for discovering TCM in treating PF were prospectively discussed. These research work have shown the therapeutic benefits of TCM in the treatment of PF. However, more continued researches should be undertaken to clarify the unconfirmed chemical composition and regulatory mechanisms, conduct standard clinical trials, and evaluate the possible side effects. The insights provided in present review will be needed for further exploration of botanical drugs in the development of PF therapy.
登录
查看更多内容
DOI：
10.1016/j.biocel.2008.06.010
发表时间：
2009-01
影响因子：
4
作者：
Aggarwal, Bharat B.;Harikumar, Kuzhuvelil B.
通讯作者：
Harikumar, Kuzhuvelil B.
影响因子：
5.1
作者：
Akgedik, Recep;Akgedik, Sukran;Yildirim, Zeki
通讯作者：
Yildirim, Zeki
柚皮苷对百草枯所致小鼠急性肺损伤和肺纤维化的保护作用
影响因子：
4.3
作者：
Chen, Yan;Nie, Yi-chu;Li, Pei-bo
通讯作者：
Li, Pei-bo
影响因子：
7.9
作者：
Boskabady, M. H.;Mohsenpoor, N.;Takaloo, L.
通讯作者：
Takaloo, L.
影响因子：
5.1
作者：
Divya, Thomas;Dineshbabu, Vadivel;Sudhandiran, Ganapasam
通讯作者：
Sudhandiran, Ganapasam